Concord Biotech Q1 FY27: net profit up 33% to ₹58.53 crore, revenue up 26%
Concord Biotech (CONCORDBIO) said it has published its Q1 FY27 results (consolidated), reporting revenue of ₹257 crore (+26.2% year on year), net profit of ₹58.53 crore (+32.8%), earnings per share of ₹5.52. The company is valued at about ₹14,388 crore.
What happened
In a filing with the BSE on 27 October 2026 at 07:03 PM, Concord Biotech (CONCORDBIO) said that it has published its Q1 FY27 results (consolidated), reporting revenue of ₹257 crore (+26.2% year on year), net profit of ₹58.53 crore (+32.8%), earnings per share of ₹5.52.
From the filing: "Tuesday, October 27, 2026, has inter-alia considered and approved the Un-audited financial results for the quarter ...."
Company snapshot
Concord Biotech is a small-cap company in the Healthcare sector, with a market value of about ₹14,388 crore.
The stock last traded at ₹1,375.3, against a 52-week range of ₹987–₹1,615 (14.8% below the high).
Before this filing the shares had moved −19.8% over the month and −1.5% over three months. Average daily turnover over the last 20 sessions was about ₹13.89 crore.
Promoters held 44.08% at the end of Q1 FY27. Foreign institutions owned 7.52% and domestic institutions 9.36%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 204 | 44.1 | 4.21 |
| Q2 FY26 | 247 | 63.6 | 6.03 |
| Q3 FY26 | 278 | 64.5 | 6.08 |
| Q4 FY26 | 326 | 88.8 | 8.46 |
| Q1 FY27 | 257 | 58.5 | 5.52 |
What history shows
This is not the company's first results disclosure: BCEIE has 3 earlier filings of this kind on record since May 2026.
After those filings, the stock gained 7.3% on average the next trading day and was up 9.2% on average after five days (3 filings with price data).
Across 300 similar disclosures by other Healthcare companies, shares moved +0.9% on average the next day and +1.8% over five days; 55% of them rose the next day.
Market-wide, 9,766 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 31 Jul 2026 | , the financial results for the period ended Jun 30, 2026. | −0.1% | −0.1% |
| 30 May 2026 | , the financial results for the period ended March 31, 2026. | +10.9% | +13.8% |
| 29 May 2026 | Audited Standalone And Consolidated Financial Results For The Fourth… | +10.9% | +13.8% |
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 27 October 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
- Concord Biotech shareholders approve bonus issue and capital hike
- Concord Biotech - Positive Breakout: These 5 stocks cross above their 200 DMAs
- Concord Biotech Ltd Faces Technical Downgrade Amid Bearish Momentum
- Concord Biotech Ltd Technical Momentum Shifts Amid Mixed Market Signals
- Concord Biotech Ltd Faces Mildly Bearish Technical Shift Amid Mixed Momentum Signals
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.